Citations

Clear

1011 citation(s) found for "Barry, WT".

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, Nancy L. , Costello, Brian A. , LaPlant, Betsy, Ansell, Stephen M. , Reeder, Craig B. , Thye, Lim Soon, Anderson, Daniel M. , Krysiak, Kilannin , Ramirez, Cody A. , Qi, Jing , Siegel, Barry A. , Griffith, Malachi , Griffith, Obi L. , Gomez, Felicia , Fehniger, Todd A. , LaPlant, Betsy R, Krysiak, Kilannin , Griffith, Malachi , Griffith, Obi L , Gomez, Felicia , Fehniger, Todd A , Bartlett, Nancy L , Kuruvilla, John , Ramirez, Cody

Mayo Clinic

Blood | October 26, 2017 | Volume: 131 | Issue: 2 | Pages: 182-190

10.1182/blood-2017-09-804641 | PMID 29074501 Get It

Key Points Ibrutinib has modest activity in FL with low response rates in rituximab-refractory patients. CARD11 mutations predict for lack of response to ibrutinib.
Right Heart Dysfunction and Failure in Heart Failure with Preserved Ejection Fraction: Mechanisms and Management. Position Statement on Behalf of the Heart Failure Association of the European Society of Cardiology
Gorter, Thomas M. , Veldhuisen, Dirk J. van , Borlaug, Barry A. , Čelutkienė, Jelena , Crespo‐Leiro, María G. , Guazzi, Marco , Harjola, Veli‐Pekka, Heymans, Stéphane , Hill, Loreena , Lund, Lars H. , Mebazaa, Alexandre , Mueller, Christian, Paulus, Walter J. , Pieske, Burkert , Piepoli, Massimo , Seferović, Petar , Solomon, Scott D. , Shah, Sanjiv J. , Wachter, Rolf , Tschöpe, Carsten , Boer, Rudolf A. de , de Boer, Rudolf A , Borlaug, Barry A , Shah, Sanjiv J , Heymans, Stephane , Bauersachs, Johann , Coats, Andrew J.S. , Harjola, Veli‐Pekka , Lainščak, Mitja , Lam, Carolyn S.P. , Lyon, Alexander R. , Ruschitzka, Frank T. , Rutten, Frans Hendrik , Solomon, Scott David , Triposkiadis, Filippos K. , Tschöpe, Carsten , Celutkiene, Jelena , Crespo-Leiro, Maria Generosa

Mayo Clinic

European Journal of Heart Failure | October 17, 2017 | Volume: 20 | Issue: 1 | Pages: 16-37

10.1002/ejhf.1029 | PMID 29044932 Get It

Abstract There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.
Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
Chertow, Glenn M. , Cheung, Alfred K. , Greene, Tom , Wei, Guo , Campbell, Ruth , Conroy, Margaret, Haley, William E. , Horwitz, Edward , Kitzman, Dalane W. , Lash, James P. , Pisoni, Roberto, Riessen, Erik, Rosendorff, Clive , Watnick, Suzanne , Whittle, Jeff , Whelton, Paul K. , Haley, William, Greene, Tom , Beddhu, Srinivasan , Cushman, William C. , Rahman, Mahboob , Freedman, Barry I. , Papademetriou, Vasilios

Mayo Clinic

Circulation | October 11, 2017 | Volume: 137 | Issue: 2 | Pages: 134-143

10.1161/circulationaha.117.030848 | PMID 29021322 Get It

Background: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear. Methods: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP. Results: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level ( P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57–1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61–0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events. Conclusions: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01206062.
Physiological Dead Space and Arterial Carbon Dioxide Contributions to Exercise Ventilatory Inefficiency in Patients with Reduced or Preserved Ejection Fraction Heart Failure
Iterson, Erik H. Van , Johnson, Bruce D. , Borlaug, Barry A. , Olson, Thomas P. , Van Iterson, Erik H , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | October 8, 2017 | Volume: 19 | Issue: 12 | Pages: 1675-1685

10.1002/ejhf.913 | PMID 28990307 Get It

Abstract Aims Patients with heart failure (HF) with reduced (HFrEF) or preserved (HFpEF) ejection fraction demonstrate an increased ventilatory equivalent for carbon dioxide (V̇E/V̇CO2) slope. The physiological correlates of the V̇E/V̇CO2 slope remain unclear in the two HF phenotypes. We hypothesized that changes in the physiological dead space to tidal volume ratio (VD/VT) and arterial CO2 tension (PaCO2) differentially contribute to the V̇E/V̇CO2 slope in HFrEF vs. HFpEF. Methods and results Adults with HFrEF (n = 32) and HFpEF (n = 27) [mean ± standard deviation (SD) left ventricular ejection fraction: 22 ± 7% and 61 ± 9%, respectively; mean ± SD body mass index: 28 ± 4 kg/m2 and 33 ± 6 kg/m2, respectively; P &lt; 0.01] performed cardiopulmonary exercise testing with breath-by-breath ventilation and gas exchange measurements. PaCO2 was measured via radial arterial catheterization. We calculated the V̇E/V̇CO2 slope via linear regression, and VD/VT = 1 − [(863 × V̇CO2)/(V̇E × PaCO2)]. Resting VD/VT (0.48 ± 0.08 vs. 0.41 ± 0.11; P = 0.04), but not PaCO2 (38 ± 5 mmHg vs. 40 ± 3 mmHg; P = 0.21) differed between HFrEF and HFpEF. Peak exercise VD/VT (0.39 ± 0.08 vs. 0.32 ± 0.12; P = 0.02) and PaCO2 (33 ± 6 mmHg vs. 38 ± 4 mmHg; P &lt; 0.01) differed between HFrEF and HFpEF. The V̇E/V̇CO2 slope was higher in HFrEF compared with HFpEF (44 ± 11 vs. 35 ± 8; P &lt; 0.01). Variance associated with the V̇E/V̇CO2 slope in HFrEF and HFpEF was explained by peak exercise VD/VT (R2 = 0.30 and R2 = 0.50, respectively) and PaCO2 (R2 = 0.64 and R2 = 0.28, respectively), but the relative contributions of each differed (all P &lt; 0.01). Conclusions Relationships between the V̇E/V̇CO2 slope and both VD/VT and PaCO2 are robust, but differ between HFpEF and HFrEF. Increasing V̇E/V̇CO2 slope appears to be strongly explained by mechanisms influential in regulating PaCO2 in HFrEF, which contrasts with the strong role of increased VD/VT in HFpEF.
Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium
Lourens, Spencer, Liangpunsakul, Suthat , Chalasani, Naga , Shah, Vijay H. , Kamath, Patrick S. , Puri, Puneet, Katz, Barry P., Radaeva, Svetlana , Crabb, David W. , Liangpunsakul, Suthat , Crabb, David W , Comerford, Megan , Sanyal, Arun J. , Puri, Puneet

Mayo Clinic

Alcoholism: Clinical and Experimental Research | October 5, 2017 | Volume: 41 | Issue: 12 | Pages: 2000-2006

10.1111/acer.13515 | PMID 28981151 Get It

The TREAT Consortium has carried out clinical studies on alcoholic hepatitis (AH) for over 4 years. We encountered problems with participant recruitment, retention, and eligibility for specific protocols. To improve our ability to carry out such trials, we reviewed recruitment screening logs, end of study logs, and surveyed study coordinators to learn the reasons for missing patients, why patients declined enrollment, and the number of patients eligible for treatment trials. Associations of the recruited subjects’ demographics with their adherence to follow‐up appointments were examined. Three hundred eight‐seven patients (AH and heavy drinking controls) were enrolled in the observational study, and 55 AH patients were recruited into treatment trials. About half of patients identified with AH could not be recruited; no specific reason could be determined for about two‐thirds of these. Among the patients who gave a reason for not participating, the most common reasons were feeling too sick to participate, desire to concentrate on abstinence, and lack of interest in research. Approximately a quarter of the AH patients met eligibility criteria for treatment trials for moderate or severe AH and we were able to recruit half to two‐thirds of those eligible. Approximately 35% of participants in the observational study returned for both 6‐ and 12‐month follow‐up visits. We did not identify biopsychosocial or demographic correlates of retention in the study. This analysis revealed that attempts at recruitment into trials for AH miss some subjects because of structural issues surrounding their hospital admission, and encounter a high rate of patient refusal to participate. Nonetheless, more than half of the patients who met the eligibility criteria for moderate or severe AH were entered into clinical trials. Retention rates for the observational study are relatively low. These findings need to be accounted for in clinical trial design and power analysis.
Resting and Exercise Haemodynamics in Relation to Six-Minute Walk Test in Patients with Heart Failure and Preserved Ejection Fraction
Wolsk, Emil , Kaye, David M. , Borlaug, Barry A. , Kitzman, Dalane W. , Komtebedde, Jan , Ponikowski, Piotr , Shah, Sanjiv J. , Gustafsson, Finn , Borlaug, Barry A , Kaye, David M , Shah, Sanjiv J , Burkhoff, Daniel , Lam, Carolyn S.P. , Ponikowski, Piotr , Gustafsson, Finn

Mayo Clinic

European Journal of Heart Failure | September 26, 2017 | Volume: 20 | Issue: 4 | Pages: 715-722

10.1002/ejhf.976 | PMID 28949052 Get It

Abstract Aims Patients with heart failure and preserved ejection fraction (HFpEF) are characterized by functional impairment and an abnormal haemodynamic response to exercise. The six-minute walk test (6MWT) serves as a standardized test for functional capacity quantification in heart failure patients, and is associated with cardiovascular outcomes. However, as the association between 6MWT and haemodynamic parameters during rest and exercise in HFpEF patients is unknown, we sought to elucidate this relationship. Methods and results Overall, 64 patients enrolled in the REDUCE LAP-HF trial completed a 6MWT at baseline. Univariate and multivariable linear regression models were used to assess the associations between 6MWT and measured or derived haemodynamic variables at baseline, during light/moderate exercise (20 W), and at peak supine exercise. The average 6MWT distance was 318 ± 106 m. At rest, in a multivariable model, only pulmonary capillary wedge pressure (PCWP) was significantly associated with 6MWT [coefficient: –5.4, 95% confidence interval (CI) –10.4, –0.5, P = 0.033]. During light/moderate exercise, mean pulmonary artery pressure was associated with 6MWT in a multivariable model (coefficient: –3.5, 95% CI –6.8, –0.3, P = 0.033). During peak exercise, central venous pressure, cardiac index (CI), and PCWP/CI correlated with 6MWT; however, workload corrected PCWP was the only variable independently associated with 6MWT (coefficient: –0.8, 95% CI –1.3, –0.4, P &lt; 0.001). The variance in 6MWT was modestly explained by measured or derived haemodynamic variables at rest or at any stage of exercise (r2 = 7–17%). Conclusion Workload corrected PCWP correlated best with 6MWT performance in HFpEF patients. Baseline haemodynamic variables were modestly correlated with 6MWT, suggesting that 6MWT performance in HFpEF patients may be significantly influenced by extra-cardiac factors.
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations
Durham, Benjamin H. , Getta, Bartlomiej , Won, Helen , Scott, Sasinya N., Chung, Young Rock , Chung, Stephen S. , Hüllein, Jennifer , Walther, Tatjana, Wang, Lu , Oakes, Christopher C. , Tibes, Raoul , Haferlach, Torsten , Taylor, Barry S. , Tallman, Martin S. , Park, Jae H. , Bogenberger, James M. , Abdel-Wahab, Omar , Dietrich, Sascha , Taylor, Justin , Kim, Eun Hee , Lu, Sydney X. , Berger, Michael , Zenz, Thorsten , Abdel‐Wahab, Omar , Durham, Benjamin

Mayo Clinic

Blood | August 11, 2017 | Volume: 130 | Issue: 14 | Pages: 1644-1648

10.1182/blood-2017-01-765107 | PMID 28801450 Get It

Key Points KMT2C mutations occur in 15% and 25% of patients with cHCL and vHCL, respectively, along with CCND3 and U2AF1 mutations each in 13% of vHCLs. NF1, NF2, N/KRAS, and IRS1 alterations contribute to clinical resistance to vemurafenib treatment in patients with cHCL.
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
Nguyen, Tien, Barry, Mary , Turner, Mallory, Crosby, Catherine, Trujillo, Miguel, Morris, John, Barry, Michael, Barry, Michael A. , Turner, Mallory A., Crosby, Catherine M. , Trujillo, Miguel A., Barry, Michael A

Mayo Clinic

Biomedicines | August 10, 2017 | Volume: 5 | Issue: 3 | Pages: 46

10.3390/biomedicines5030046 | PMID 28796161 Get It

Oncolytic viruses would ideally be of use for systemic therapy to treat disseminated cancer. To do this safely, this may require multiple layers of cancer specificity. The pharmacology and specificity of oncolytic adenoviruses can be modified by (1) physical retargeting, (2) physical detargeting, (3) chemical shielding, or (4) by modifying the ability of viral early gene products to selectively activate in cancer versus normal cells. We explored the utility of these approaches with oncolytic adenovirus serotype 5 (Ad5) in immunocompetent Syrian hamsters bearing subcutaneous HaK tumors. After a single intravenous injection to reach the distant tumors, the physically hepatocyte-detargeted virus Ad5-hexon-BAP was more effective than conditionally replicating Ad5-dl1101/07 with mutations in its E1A protein. When these control or Ad5 treated animals were treated a second time by intratumoral injection, prior exposure to Ad5 did not affect tumor growth, suggesting that anti-Ad immunity neither prevented treatment nor amplified anti-tumor immune responses. Ad5-dl1101/07 was next chemically shielded with polyethylene glycol (PEG). While 5 kDa of PEG blunted pro-inflammatory IL-6 production induced by Ad5-dl1101/07, this shielding reduced Ad oncolytic activity.
Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure
Melenovský, Vojtěch , Beneš, Jan , Franeková, Janka , Kovar, Jan, Borlaug, Barry A. , Segeťová, Markéta , Pelikánová, T, Borlaug, Barry A , Kovář, Jan , Tura, Andrea , Melenovský, Vojtěch

Mayo Clinic

Journal of the American Heart Association | August 8, 2017 | Volume: 6 | Issue: 8 | Pages: No page available

10.1161/jaha.116.005290 | PMID 28784650 Get It

Background The mechanisms and relevance of impaired glucose homeostasis in advanced heart failure ( HF ) are poorly understood. The study goals were to examine glucose regulation, pancreatic endocrine function, and metabolic factors related to prognosis in patients with nondiabetic advanced HF. Methods and Results In total, 140 advanced HF patients without known diabetes mellitus and 21 sex‐, age‐, and body mass index–matched controls underwent body composition assessment, oral glucose tolerance testing, and measurement of glucose‐regulating hormones to model pancreatic β‐cell secretory response. Compared with controls, HF patients had similar fasting glucose and insulin levels but higher levels after oral glucose tolerance testing. Insulin secretion was not impaired, but with increasing HF severity, there was a reduction in glucose, insulin, and insulin/glucagon ratio—a signature of starvation. The insulin/C‐peptide ratio was decreased in HF , indicating enhanced insulin clearance, and this was correlated with lower cardiac output, hepatic insufficiency, right ventricular dysfunction, and body wasting. After a median of 449 days, 41% of patients experienced an adverse event (death, urgent transplant, or assist device). Increased glucagon and, paradoxically, low fasting plasma glucose displayed the strongest relations to outcome ( P =0.01). Patients in the lowest quartile of fasting plasma glucose (3.8–5.1 mmol·L −1 , 68–101 mg·dL −1 ) had 3‐times higher event risk than in the top quartile (6.0–7.9 mmol·L −1 , 108–142 mg·dL −1 ; relative risk: 3.05 [95% confidence interval, 1.46–6.77]; P =0.002). Conclusions Low fasting plasma glucose and increased glucagon are robust metabolic predictors of adverse events in advanced HF . Pancreatic insulin secretion is preserved in advanced HF , but levels decrease with increasing HF severity due to enhanced insulin clearance that is coupled with right heart failure and cardiac cachexia.
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Konstantinopoulos, Panagiotis A. , Barry, William T., Birrer, Michael J. , Farooq, Sarah , Cadoo, Karen A. , Whalen, Christin, Luo, Weixiu, Liu, Hui , Aghajanian, Carol , Taylor, Barry S. , Won, Helen , Palakurthi, Sangeetha , Cantley, Lew, D’Andrea, Alan D. , Matulonis, Ursula A. , Westin, Shannon N , Solit, David B. , Mills, Gordon B. , Berger, Michael , Liu, Joyce F. , Kaufmann, Scott H. , Swisher, Elizabeth M. , Winer, Eric P. , Wulf, Gerburg M. , Konstantinopoulos, Panagiotis A , D'Andrea, Alan

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: CT008-CT008

10.1158/1538-7445.am2017-ct008 Get It

Abstract Background: In vivo synergy with concurrent PI3-Kinase inhibition and PARP inhibition has been observed in BRCA-deficient and BRCA-proficient preclinical models of triple negative breast cancer (TNBC) and ovarian cancer (OC). A phase I trial of the oral pan-class I PI3-Kinase inhibitor BKM120 and the PARP inhibitor olaparib demonstrated anti-cancer activity in TNBC and OC, both in patients with and without germline BRCA1 and BRCA2 (BRCA) mutations. However, CNS toxicity (depression) and liver function test abnormalities limited dose escalation of BKM120 prompting evaluation of the alpha specific PI3-Kinase inhibitor BYL719 (which has no CNS toxicity) in combination with olaparib. Methods: Olaparib was administered twice daily (tablet formulation) and BYL719 daily on a 28-day cycle, both orally. A 3 + 3 dose-escalation design was employed with primary objectives of defining the maximum tolerated dose (MTD) and recommended phase 2 dose of the combination of BYL719 and olaparib, and secondary objectives of defining toxicity, activity, and pharmacokinetic profiles of both agents. Eligibility included recurrent TNBC or high grade serous (HGS) OC, or any histology OC or breast cancer (BC) with presence of a known germline BRCA mutation, performance status of 0-1 and measurable/evaluable cancer. Patients with platinum sensitive or resistant or refractory OC were eligible and prior PARP inhibitor use was allowed. Dose-expansion cohorts at the MTD were enrolled for both BC and OC. Results: 46 patients (16 BC and 30 OC) have been enrolled in the study; 28 patients participated in the dose escalation portion of the study (4 BC and 24 OC). Two patients with OC did not receive study drugs because of ineligibility. MTD was defined as BYL719 200mg once daily and olaparib 200mg twice daily. Dose limiting toxicities included hyperglycemia, rash and fever with decreased neutrophil count. Four patients (3 OC and 1 BC) discontinued protocol therapy because of toxicity (2 for hyperglycemia, 1 for nausea and 1 for allergic reaction). Most common toxicities included nausea, hyperglycemia, fatigue, diarrhea and vomiting. At the MTD, 6 patients with OC and 12 patients with BC were enrolled into a dose expansion cohort. The OC expansion cohort has completed enrollment, while the BC cohort is still enrolling. Among patients with OC who received study drugs (28 patients, 26 (93%) with platinum resistant disease), objective response rate (ORR) by RECIST 1.1 was 36% (10/28 patients, all partial responses (PRs)). Median duration of response was 167 days (range 16-398 days); 5 of 10 patients with PR remain on treatment. ORR was 33% for patients with germline BRCA mutations and 31% for patients without germline BRCA mutations. Among patients without germline BRCA mutations with platinum resistant OC, ORR was 29%. Conclusions: Combined BYL719 and olaparib is feasible, and similar clinical benefit was observed in patients with and without germline BRCA mutations. The activity of this combination in OC patients without germline BRCA mutations and with platinum resistant disease was higher than expected from olaparib monotherapy and warrants further investigation. This work was funded in part by the Stand Up To Cancer Ovarian Dream Team. Clinical trial: NCT01623349. Citation Format: Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Sarah Farooq, Karen Cadoo, Christin Whalen, Weixiu Luo, Hui Liu, Carol Aghajanian, David B. Solit, Gordon B. Mills, Barry S. Taylor, Helen Won, Michael F. Berger, Sangeetha Palakurthi, Joyce F. Liu, Lew Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis. Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT008. doi:10.1158/1538-7445.AM2017-CT008